Teva responds to Mylan backlash with planned launch of generic EpiPen | Healthcare Finance News
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
Teva, Mylan to jumpstart production of old malaria drug to fight coronavirus
Mylan board rejects Teva takeover bid
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
Teva Pharmaceutical Industries' quest to acquire Mylan NV could wind up in a Dutch court - Pittsburgh Business Times
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
Mylan rejects Teva takeover bid as too low | Mint
Teva-Makes-Hostile-Bid-Acquire
Teva drops bid for Mylan, buys Allergan's generic drug unit - Philadelphia Business Journal
Generic EpiPen by Teva Wins FDA Nod After 2 Year Delay | Fierce Pharma
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Federal Circuit Upholds Mylan's U.S. Patents on Perforomist® Inhalation Solution; Decision Prevents Approval of Teva ANDA
Mylan (MYL) Stock Tanks After Teva Withdraws Takeover Bid - TheStreet
20 States Accuse Generic Drug Companies of Price Fixing - The New York Times
Teva settles litigation with Mylan over Nuvigil - Pharmaceutical Technology
Teva withdraws proposal to acquire Mylan
Teva, Mylan Drop on Announcement of Epinephrine Injector Rival | Ctech
Drugmaker Teva makes $40B bid for rival Mylan
Teva/Mylan: brand management | Financial Times
In blow to Teva, UK court rules in favor of Copaxone patent challenge | The Times of Israel
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid | Reuters
